Largest one day gains
The 50 largest one day percentage moves higher recorded at the latest close. The largest moves were ABCL at +17.8% and GENB at +15.0%. By size, the list splits into 2 mega cap, 8 large cap and 40 mid cap listings.
Switch view
All stocks50 of 23,178 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1D return | 1Y return |
|---|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | $4.05B | Mid cap | +17.81% | +195.51% |
| GENB | Generate Biomedicines, Inc. | $2.27B | Mid cap | +15.01% | +61.11% |
| MRNA | Moderna, Inc. | $63.41B | Large cap | +14.36% | +526.55% |
| BEAM | Beam Therapeutics Inc. | $3.21B | Mid cap | +9.53% | +88.75% |
| GRAL | GRAIL, Inc. | $3.69B | Mid cap | +7.78% | +150.69% |
| QURE | uniQure N.V. | $3.54B | Mid cap | +7.56% | +228.30% |
| TWST | Twist Bioscience Corporation | $9.50B | Mid cap | +7.54% | +452.83% |
| KLRA | Kailera Therapeutics, Inc. | $2.14B | Mid cap | +7.32% | −31.73% |
| CAI | Caris Life Sciences, Inc. | $7.38B | Mid cap | +7.19% | −27.21% |
| CDNA | CareDx, Inc. | $2.63B | Mid cap | +6.95% | +298.43% |
| MRVI | Maravai LifeSciences Holdings, Inc. | $3.33B | Mid cap | +6.76% | +275.00% |
| CRSP | CRISPR Therapeutics AG | $5.89B | Mid cap | +6.70% | +12.51% |
| ZBIO | Zenas BioPharma, Inc. | $2.20B | Mid cap | +6.70% | +103.93% |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.32B | Mid cap | +6.39% | +46.03% |
| VCYT | Veracyte, Inc. Common Stock | $3.54B | Mid cap | +6.20% | +49.04% |
| IDYA | IDEAYA Biosciences, Inc. | $4.10B | Mid cap | +6.09% | +71.91% |
| KOD | Kodiak Sciences Inc. | $2.48B | Mid cap | +6.02% | +316.68% |
| NVCR | NovoCure Limited | $2.05B | Mid cap | +5.13% | +50.60% |
| BHVN | Biohaven Ltd. | $2.17B | Mid cap | +5.12% | −3.75% |
| NUVB | Nuvation Bio Inc. | $2.49B | Mid cap | +5.03% | +146.53% |
| SMMT | Summit Therapeutics Inc. | $10.66B | Large cap | +4.95% | −49.14% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +4.91% | +196.22% |
| RCUS | Arcus Biosciences, Inc. | $4.02B | Mid cap | +4.81% | +211.03% |
| CMPS | COMPASS Pathways plc | $2.06B | Mid cap | +4.79% | +224.89% |
| RGC | Regencell Bioscience Holdings Limited | $2.74B | Mid cap | +4.73% | −54.89% |
| IOVA | Iovance Biotherapeutics, Inc. | $3.82B | Mid cap | +4.71% | +233.60% |
| NBTX | Nanobiotix S.A. | $2.11B | Mid cap | +4.66% | +321.42% |
| VERA | Vera Therapeutics, Inc. | $2.54B | Mid cap | +4.63% | +65.32% |
| KYMR | Kymera Therapeutics, Inc. | $10.53B | Large cap | +4.62% | +202.82% |
| QGEN | Qiagen N.V. | $9.01B | Mid cap | +4.48% | −10.74% |
| KRYS | Krystal Biotech, Inc. | $10.54B | Large cap | +4.23% | +142.69% |
| MLYS | Mineralys Therapeutics, Inc. | $2.32B | Mid cap | +4.23% | +78.70% |
| RLAY | Relay Therapeutics, Inc. | $4.51B | Mid cap | +4.10% | +486.04% |
| GMAB | Genmab A/S | $21.42B | Large cap | +4.06% | +41.34% |
| ALMS | Alumis Inc. | $2.98B | Mid cap | +4.04% | +388.98% |
| ACHC | Acadia Healthcare Company, Inc. | $2.78B | Mid cap | +4.00% | +34.73% |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +3.98% | +49.66% |
| MANE | Veradermics, Incorporated | $4.11B | Mid cap | +3.95% | +171.13% |
| TEM | Tempus AI, Inc. | $12.40B | Large cap | +3.87% | −9.45% |
| TSHA | Taysha Gene Therapies, Inc. | $2.02B | Mid cap | +3.85% | +112.33% |
| MRK | Merck & Co., Inc. | $371.70B | Mega cap | +3.84% | +88.17% |
| RAPP | Rapport Therapeutics, Inc. | $2.46B | Mid cap | +3.73% | +249.76% |
| NVO | Novo Nordisk A/S | $215.18B | Mega cap | +3.71% | −10.46% |
| MCK | McKesson Corporation | $105.52B | Large cap | +3.58% | +33.71% |
| DFTX | Definium Therapeutics, Inc. | $6.02B | Mid cap | +3.56% | +354.92% |
| STOK | Stoke Therapeutics, Inc. | $2.16B | Mid cap | +3.53% | +77.32% |
| BLLN | BillionToOne, Inc. | $4.72B | Mid cap | +3.45% | −8.14% |
| PTCT | PTC Therapeutics, Inc. Common Stock | $6.13B | Mid cap | +3.39% | +49.03% |
| MBX | MBX Biosciences, Inc. | $3.30B | Mid cap | +3.36% | +394.02% |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +3.31% | +9.42% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.
Micro and small cap listings are left out, so the list describes the market rather than thin trading, as are moves beyond 1,000% in a session, which are corporate actions the price series has not been restated for. This is a description of one day of price movement, nothing more. It says nothing about any company behind it.